This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -35.56% and -27.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock
by Zacks Equity Research
Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 24.32% and -2.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -4.76% and -13.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 40.26% and 33.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
by Zacks Equity Research
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?
by Zacks Equity Research
Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.